The Taiwan-ASEAN Investment Strategy Partner Forum, organized by the Ministry of Economic Affairs’s (MOEA) Department of Investment Services, was held at the Taipei International Conference Center today (the 13th).

According to WHO, currently, more than 55 million people live with dementia worldwide, and there are nearly 10 million new cases every year. The most common type (60-70%) of dementia is Alzheimer’s disease (AD), a progressive disease characterized by memory loss, language breakdown, and eventually, death. The main pathological factor for AD is thought to be the progressive accumulation of amyloid beta (Aβ) peptides in the brain, generated by the cleavage of the amyloid precursor protein (APP) by a combination of β-secretases and γ-secretases. Hyperphosphorylation of tau, a microtubule-associated protein which aggregates to form tangles, also damages the brains of patients with AD. This year, we’re excited to announce that ANKASCIN® 568 product has successfully received a health certificate for “Anti-aging” Support. SunWay research demonstrates the protective effect of ANKASCIN® 568 in 4 aging models: Amyloid β-Infused Rats In this study, the effects of dietary administration of ANKASCIN® 568 on memory and learning abilities are confirmed in an animal model of AD rats infused with Aβ40 into the cerebral ventricle. During continuous Aβ40 infusion for 28 days, ANKASCIN® 568 administration potently reverses the memory deficit in the memory task. Aβ40 infusion increases acetylcholinesterase activity, reactive oxygen species, and lipid peroxidation and decreases total antioxidant status and superoxide dismutase activity in brain, but these damages were potently reversed by ANKASCIN® 568 administration. The protection provided […]

The Certficate of 2010 Symbol of National Quality